ALT

1.3305.67%
CA

Catherine Angell Sohn

Independent Director

Dr. Catherine Angell Sohn, Pharm. D., CLP, also known as Cathy, serves as Member of Scientific Advisory Board. She served as Independent Director of Altimmune, Inc. since March 2023. She had been a Director of Maze Therapeutics, Inc. since January 2021 and serves as Independent Non-Employee Director. Dr. Sohn served as an Independent Director of Axcella Health Inc. since August 21, 2019 until November 01, 2023. Dr. Sohn served as Director at Maze Therapeutics since March 01, 2021 until June 8, 2026. Since January 2011, Dr. Sohn has consulted for pharmaceutical, biotechnology, medical device and consumer healthcare companies in the areas of business strategy, business development and strategic product development at Sohn Health Strategies, LLC, which she founded and serves as President. Dr. Sohn served as Senior Vice President of Business Development and Strategic Alliance, GSK Consumer Healthcare, at GlaxoSmithKline from 1998 to 2010, where she spear Headed a series of U.S. and global licensing, merger and acquisition transactions. Since 2010, Dr. Sohn consults to pharmaceutical, biotechnology, medical device and consumer healthcare companies in the areas of business strategy, business development and strategic product development. Dr. Sohn is an experienced public company Director, former global biopharmaceutical executive, Adjunct Professor and a Certified Licensing Professional (CLP) Emeritus. Her areas of expertise include domestic and global business development, strategy and product marketing/launch execution across vaccines, pharmaceutical products and consumer healthcare brands, having led the launches of the U.S. Vaccine Business CNS pharmaceutical product at SmithKline Beecham (now GlaxoSmithKline). From 1982 to 1986, Dr. Sohn served in the anti-infective medical affairs department and from 1986 to 1993 as Director in US Marketing at SmithKline & French and SmithKline Beecham. From 1982 to 2010, she was with GlaxoSmithKline plc after holding various pharmaceutical, vaccine and consumer healthcare leadership positions. She served as Senior Vice President of Worldwide Business Development and Strategic Alliances for consumer healthcare division at GlaxoSmithKline plc, where she led numerous U.S., global, European and Japanese M&A and licensing transactions and integrations. Early in her tenure with GSK, Dr. Sohn established the U.S. vaccine business unit for SmithKline Beecham Pharmaceuticals from 1986 to 1990 and led the commercialization of Engerix-B Vaccine. Subsequently, she led the commercialization of Paxil, which became one of GSK’s top five products in the U.S. She is Founder and CTO of ACCB Biotech since January 01,2004. Dr. Sohn joined Smith Kline & French (now GSK) in anti-infective medical affairs and later acted as Vice President for worldwide strategic product development for the cardiovascular, pulmonary and metabolic therapeutic areas from 1994 to 1998 with responsibility for product strategy, valuation and strategic commercial leadership of assets from Phase 1 through global life cycle management from 1994 to 1997. She was a Member of the global executive team for strategic product development. She was the Product Marketing Director for the successful U.S. launch of the company's central nervous system product from 1990 to 1993. Dr. Sohn began her pharmaceutical career at SmithKline & French in the Anti-infective Medical Affairs group in 1982. She has been a Director of The F. Dohmen Co. since 2012. She serves as Partner at Tsingyuan Ventures since January 01, 2017. She has been a Director at Armis Biopharma, Inc. (formerly known as CHD Bioscience, Inc.). since February 03, 2014. She has been Director of Ariel Pharmaceuticals, Inc. since April 5, 2012. She had been an Independent Director at Jazz Pharmaceuticals Public Limited Company since July 27, 2012 until July 25, 2024. She is a Board member, World Affairs Council of Philadelphia. Dr. Sohn served as an Independent Director at Seneca Biopharma, Inc. (formerly Neuralstem, Inc.) since January 14, 2014 until May 20, 2017. She served as a Member of Health Advisory Board at Johns Hopkins Bloomberg School of Public Health. Since 2016, She serves as Adjunct Professor at UCSF. Dr. Sohn is Dean’s Professor and Member of the Board of Visitors at the University of Sciences in Philadelphia, PA. Dr. Sohn started her career as Assistant Professor of Clinical Pharmacy at the University of the Sciences in Philadelphia. She serves as Director at Landec since November 01, 2012.She serves as Member of Advisory Board of Drexel Raj & Kamla Gupta Governance Institute since February 01, 2014. She serves on the Dean’s Advisory Council for Drexel University School of Public Health, Ernst & Young’s global Life Science Advisory Board and the global advisory Board of the Healthcare Business women’s Association (HBA). She has been an Independent Director of Rubius Therapeutics, Inc. since January 01, 2018. She also served as Chairman of the Board of BioEclipse Therapeutics, Inc. since August 01, 2016 until 2025 and serves as its Director. She serves as Director at Axcella since August 01, 2019.She is a Board Leadership Fellow of the National Association of Corporate Directors. She is a Governance Fellow of the National Association of Corporate Directors (NACD).She served as independent Director at Rubius Therapeutics since January 01, 2018 until February 28, 2023. She is a Member of the Springboard Enterprises' Life Science Council. She serves as Independent Director at Axcella Health (NASDAQ: AXLA). She serves as independent Director at Maze Therapeutics (privately held) since March 01, 2021.She has also served to the boards of multiple non-profit organizations, including two terms on the Member of Health Advisory Board for the Johns Hopkins University Bloomberg School of Public Health and the External Advisory Board for Drexel University Close School of Entrepreneurship. She was Vice Chair of the Corporate Executive Board of the Philadelphia Museum of Art. She served as Director of Consumer Healthcare Products Association. Dr. Sohn has received numerous awards and honors, including the University of California, San Francisco (USCF), School of Pharmacy, Alumnus of the Year in 2000; the Healthcare Business women’s Association (HBA) Woman of the Year in 2003; and the Licensing Executive Society’s Frank Barnes Mentor Award in 2009 and Distinguished Alum of the Year by the University of California, San Francisco (2000) and received the Frank Barnes Mentoring Award from the Licensing Executive Society (2009). Dr. Sohn has reputation as a strategic thinker with the ability to drive a strong interface between research and development and marketing. In 2016, Dr. Sohn was recognized as one of the PharmaVoice 100 most inspiring people in the life science industry. She is a Certified Licensing Professional (C.L.P.). She received Doctor of Pharmacy degree from the University of California, San Francisco (UCSF), School of Pharmac

Positions